Blood · 2025
Hu L, Shi Y, Hsu J, Gera J, Van Ness B, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood. 2003;101(8):3126-3135.
Источник пометил эту публикацию как отозванную.
СтатьяRetraction NoticeНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Qin, Li Lin, Nian Siji, Sun Xiaoke, Guo Xiyuan, Li Chengwen, Yang Zhihui, Ye Yingchun, Yuan Qing
Аннотация
PURPOSE: As a novel candidate in cancer immunotherapy, siglec-15-targeting antibodies hold promise for providing alternative therapeutic strategies to tumors unresponsive to programmed death ligand 1 (PD-L1) antibody therapy. To date, pharmacological development targeting siglec-15 has not yet achieved significant breakthroughs or clinical approval. Therefore, this study aims to develop a novel anti-siglec-15 antibody designed to restore tumor immune normalization.
METHODS: In this study, we constructed a phage immune library derived from lymphoid tissues of lung cancer patients using phage display technology and screened the fully human antibodies against siglec-15 antigen from this library. The antibody affinity was detected by Bio-Layer Interferometry, the binding rate of antibody to positively expressing siglec-15 tumor cells was examined by flow cytometry, and the activity of antibody-mediated killer cells against tumor cells was reflected by Antibody-Dependent Cellular Cytotoxicity (ADCC) action. The blockage of proliferation inhibition caused by siglec-15 antigen by antibodies was investigated by t-lymphocyte proliferation assays, and CD8+ T cells were collected from malignant pleural effusion specimens derived from lung cancer patients to determinewhether antibodies could alleviate the immunosuppression present in the tumor microenvironment (TME). The anti-tumor efficacy of the antibody was investigated in vivo by constructing a zebrafish tumor model and a humanized mouse tumor model.
RESULTS: The antibody demonstrated nanomolar affinity and specificity, enhanced antibody-dependent cellular cytotoxicity (ADCC) against tumor cells, reversed T-cell suppression, and reduced CD8+ T-cell exhaustion in vitro analyses. In vivo models confirmed tumor growth inhibition via increased lymphocyte infiltration and activation.
CONCLUSION: Antibody immune libraries from lymphoid tissues of lung cancer patients can screen specific antibodies against siglec-15 target antigens and exert certain biological functions in vitro and in vivo.
METHODS: In this study, we constructed a phage immune library derived from lymphoid tissues of lung cancer patients using phage display technology and screened the fully human antibodies against siglec-15 antigen from this library. The antibody affinity was detected by Bio-Layer Interferometry, the binding rate of antibody to positively expressing siglec-15 tumor cells was examined by flow cytometry, and the activity of antibody-mediated killer cells against tumor cells was reflected by Antibody-Dependent Cellular Cytotoxicity (ADCC) action. The blockage of proliferation inhibition caused by siglec-15 antigen by antibodies was investigated by t-lymphocyte proliferation assays, and CD8+ T cells were collected from malignant pleural effusion specimens derived from lung cancer patients to determinewhether antibodies could alleviate the immunosuppression present in the tumor microenvironment (TME). The anti-tumor efficacy of the antibody was investigated in vivo by constructing a zebrafish tumor model and a humanized mouse tumor model.
RESULTS: The antibody demonstrated nanomolar affinity and specificity, enhanced antibody-dependent cellular cytotoxicity (ADCC) against tumor cells, reversed T-cell suppression, and reduced CD8+ T-cell exhaustion in vitro analyses. In vivo models confirmed tumor growth inhibition via increased lymphocyte infiltration and activation.
CONCLUSION: Antibody immune libraries from lymphoid tissues of lung cancer patients can screen specific antibodies against siglec-15 target antigens and exert certain biological functions in vitro and in vivo.